National Security , Newsline

Trump’s Prescription Drug Price Reform Is Promising

Posted on Friday, February 15, 2019
by Outside Contributor
Trump prescription drug price reform
Official White House Photo by Tia Dufour

One part of President Trump’s State of the Union address that received bipartisan cheers was the call to lower prescription drug prices. A “next major priority for me, and for all of us,” said Trump, “should be to lower the cost of health care and prescription drugs — and to protect patients with pre-existing conditions.”

Last week Trump’s Department of Health and Human Services quietly proposed a new rule to fundamentally reform the biggest driver of rising prescription drug prices: the “Kabuki” drug rebate pricing system.

The regulation would essentially eliminate the middlemen between government health insurers and drug manufacturers known as pharmacy benefit managers (PBMs). As sole drug purchasers, PBMs ultimately decide what medicines health plans cover and how much consumers pay for them. The billions of dollars of payments, known as rebates, that PBMs demand from drug manufacturers in exchange for agreeing to place certain medications on insurance plans are the main prescription drug cost culprit. Eliminating these rebates will cause these dollars to flow back to patients in the form of lower drug prices.

Current Medicare regulations provide PBMs with a “safe harbor” from the Anti-Kickback Statute in the Social Security Act, allowing them to accept rebates that would be considered anticompetitive in other areas of the economy. This safe harbor has turned drug distribution into a pay-to-play scheme, dominated by three PBMs that control about 80 percent of prescription drug plans.

The HHS rule would end PBM control over government drug prices by eliminating this safe harbor protection. This is perhaps the single most important deregulation since the federal deregulation of transportation nearly 40 years ago. It can have the same positive effects on price, quality and innovation.

PBM rebates account for nearly the entire recent increase in prescription drug list prices. According to recent disclosures, while list prices of prescription drugs increased by 37 percent between 2011 and 2017, net prices after rebates only grew by a little more than 1 percent per year. Data from SSR Health indicates that net prices actually fell by 5.1 percent in 2018. Major manufacturers such as Merck, Sanofi and Johnson & Johnson disclosed that their net prices are actually falling. Almost every drug company that announced January 2019 list price increases revealed that the hikes were to cover rebate costs.

Rebates now account for about one-third of prescription drug sales, about $166 billion of the $455 billion spent annually. Rebates have more than doubled this decade. Because rebates are a percentage of list price, a government investigation has found that PBMs place more expensive prescription drugs on insurance plan formularies.

Where do these hundreds of billions of rebate dollars go? Most of it is passed on to insurance companies and used reduce overall premium costs for employers. While saving some money on monthly premiums is nice, it’s cold comfort for those with rare or chronic conditions who are forced to pay dramatically higher drug prices, with no direct relief at the prescription counter, as a result of this rebate system.

Roughly one-in-five patients are paying full list prices for their brand medications. A recent IMS study found that “specialty prescriptions are set based on list prices 34% of the time and that accounts for 91% of out-of-pocket spending by patients.” Rising list prices also affect covered patients because co-pay costs are generally based on them.

Ironically, these sickest patients have the prescription drug needs that generate the bulk of rebates in the first place. Just 2 percent of the sickest Americans make up about 3 percent of prescriptions dispensed but fully one-third of rebates and out-of-pocket costs. Analyzing this situation, Food and Drug Administration Chief Scott Gottlieb complained, “Sick people aren’t supposed to be subsidizing the healthy.”

Eliminating rebates “would counteract the incentives behind rising list prices,” says HHS. Given the fraction that rebates play in list prices, pharmacy counter prices could quickly come down by one-third and allow companies to offer important medicines for a few dollars a month.

Deregulating drug channels will allow — indeed, force — manufacturers to compete on prices and performance rather than cronyism and access. “This rule provides a clear pathway,” concludes HHS, “for drug companies instead to compete to have the lower price and out-of-pocket cost to the patient.”

Before transportation deregulation, trucking, airline and rail prices were set by a handful of large companies controlling transport access to particular routes rather than letting customers decide. Eliminating these controls dramatically lowered prices, improved service and increased innovation. By eliminating the PBM cartel, the same revolution can occur with prescription drugs.

Share this article:
Notify of
Most Voted
Newest Oldest
Inline Feedbacks
View all comments
Dan W.
Dan W.
5 years ago

I am wearing out my incisors with all of this nibbling around the edges of the explosive cost of prescription drugs problem.

Medicare (the largest purchaser of drugs) is currently barred by statute from negotiating drug prices with the drug companies. This prohibition was enacted by Congress and can only be undone by Congress. The President can’t lift this prohibition by Executive Order.

If we really want to take a bite out of drug prices, Congress needs pass legislation for the President’s signature to allow the CMS (a/k/a Medicare) to negotiate drug prices with the drug companies. Then we would see price reductions for prescription drugs in line with the price reductions that Medicare already gets on hospital and doctor charges.

Joe Pascucci
Joe Pascucci
5 years ago


5 years ago

WHEN??? This commentary does not indicate whether this proposed rule will be enacted or how or when.

5 years ago

This open revelation put forth by President Trump is not new, we all know that the US is a money pond of wealth and suckers willing to give away their fortunes..we support and subsidize socialistic medical around the world, this is why we who have a profitable society are paying the drug companies a major sum so they can reap a lesser profit in less wealthy countries that pay them far less….it’s just another scheme called wealth distribution wanted by the globalist world of elitism……The cries of foul around the world will get louder if he succeeds in forcing the providers to stop the gouging…?

steven jacobs
steven jacobs
5 years ago

the REAL solution-have Medicare negotiate drug prices-not to exceed 10X the price of the drug in INDIA.

An older blonde women laughing in the kitchen with a grey haired man.
AMAC’s Medicare Advisory Service
The knowledge, guidance, and choices of coverage you’re looking for. The exceptional service you deserve.
The AMAC App on 3 different iPhone
Download the AMAC App
The AMAC App is the place to go for insightful news wherever you are and whenever you want.
Joe Biden speaking with attendees
NEW YORK - OCT 10:American homeless sleeps in New York city subway on October 10 2009.A 2013 report show that the number of homeless people recorded in NYC topped 50,000 for the first time.
Former President of the United States Donald Trump speaking with attendees at the 2023 Turning Point Action Conference at the Palm Beach County Convention Center in West Palm Beach, Florida.
gen z and boomers; election - pick your side poster

Stay informed! Subscribe to our Daily Newsletter.

"*" indicates required fields

Would love your thoughts, please comment.x

Subscribe to AMAC Daily News and Games